Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC.
Patil T, Staley A, Nie Y, Sakamoto M, Stalker M, Jurica JM, Koehler K, Cass A, Kuykendall H, Schmitt E, Filar E, Reventaite E, Davies KD, Nijmeh H, Haag M, Yoder BA, Bunn PA, Schenk EL, Aisner DL, Iams WT, Marmarelis ME, Camidge DR. Patil T, et al. Among authors: schenk el. JTO Clin Res Rep. 2024 Jan 18;5(2):100637. doi: 10.1016/j.jtocrr.2024.100637. eCollection 2024 Feb. JTO Clin Res Rep. 2024. PMID: 38361741 Free PMC article.
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3.
Jaiyesimi IA, Leighl NB, Ismaila N, Alluri K, Florez N, Gadgeel S, Masters G, Schenk EL, Schneider BJ, Sequist L, Singh N, Bazhenova L, Blanchard E, Freeman-Daily J, Furuya N, Halmos B, Azar IH, Kuruvilla S, Mullane M, Naidoo J, Reuss JE, Spigel DR, Owen DH, Patel JD. Jaiyesimi IA, et al. Among authors: schenk el. J Clin Oncol. 2024 Apr 10;42(11):e23-e43. doi: 10.1200/JCO.23.02746. Epub 2024 Feb 28. J Clin Oncol. 2024. PMID: 38417098
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3.
Jaiyesimi IA, Leighl NB, Ismaila N, Alluri K, Florez N, Gadgeel S, Masters G, Schenk EL, Schneider BJ, Sequist L, Singh N, Bazhenova L, Blanchard E, Freeman-Daily J, Furuya N, Halmos B, Azar IH, Kuruvilla S, Mullane M, Naidoo J, Reuss JE, Spigel DR, Owen DH, Patel JD. Jaiyesimi IA, et al. Among authors: schenk el. J Clin Oncol. 2024 Apr 10;42(11):e1-e22. doi: 10.1200/JCO.23.02744. Epub 2024 Feb 28. J Clin Oncol. 2024. PMID: 38417091
Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity.
Kleczko EK, Hinz TK, Nguyen TT, Gurule NJ, Navarro A, Le AT, Johnson AM, Kwak J, Polhac DI, Clambey ET, Weiser-Evans M, Merrick DT, Yang MC, Patil T, Schenk EL, Heasley LE, Nemenoff RA. Kleczko EK, et al. Among authors: schenk el. NPJ Precis Oncol. 2023 Feb 4;7(1):15. doi: 10.1038/s41698-023-00355-2. NPJ Precis Oncol. 2023. PMID: 36739466 Free PMC article.
Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway.
Priest K, Le A, Gebregzabheir A, Nijmeh H, Reis GB, Mandell M, Davies KD, Lawrence C, O'Donnell E, Doebele RC, Bao L, Aisner DL, Schenk EL. Priest K, et al. Among authors: schenk el. NPJ Precis Oncol. 2023 Jan 23;7(1):9. doi: 10.1038/s41698-023-00349-0. NPJ Precis Oncol. 2023. PMID: 36690705 Free PMC article.
34 results